Literature DB >> 16839849

Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes.

John N Fain1, David S Tichansky, Atul K Madan.   

Abstract

The present studies were designed to compare the relative release of interleukin 1 receptor antagonist (IL-1Ra), cathepsin S, macrophage migration inhibitory factor (MIF), nerve growth factor (NGF), and interleukin 18 (IL-18) by adipocytes as compared with the non-fat cells present in subcutaneous and omental adipose tissue from morbidly obese gastric bypass patients as compared with obese abdominoplasty patients. The release of IL-1Ra, cathepsin S, and MIF by explants of human adipose tissue incubated for 48 hours averaged 6, 9, and 19 pmol/g, respectively, and was far greater than the release of NGF (0.05 pmol/g) or IL-18 (0.006 pmol/g). The release by human adipocytes of IL-1Ra, cathepsin S, and MIF was 0.13, 0.32, and 2.6 pmol/g, respectively, over 48 hours, whereas NGF release was 0.003 and IL-18 0.001 pmol/g. Only the total release of MIF by human adipose tissue explants was enhanced, whereas that of IL-18 was significantly reduced in explants from morbidly obese women. Most of (55%-73%) the release of IL-1Ra, cathepsin S, MIF, NGF, and IL-18 was by the adipose tissue matrix, whereas release by stromal-vascular (SV) cells was 3% to 28% of total release over 48 hours by the adipose tissue matrix, SV cells and adipocytes. The release of NGF by adipocytes was 42%, that of MIF was 27%, and for the other factors 15% or less of release over 48 hours by the adipose tissue matrix, SV cells, and adipocytes. Our results suggest that the non-fat cells in human adipose tissue contribute to most of the release of NGF, IL-18, IL-1Ra, cathepsin S, and MIF seen during primary culture of adipose tissue explants from obese women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16839849     DOI: 10.1016/j.metabol.2006.04.008

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  21 in total

Review 1.  The macrophage migration inhibitory factor protein superfamily in obesity and wound repair.

Authors:  Bong-Sung Kim; Norbert Pallua; Jürgen Bernhagen; Richard Bucala
Journal:  Exp Mol Med       Date:  2015-05-01       Impact factor: 8.718

2.  The Anti-Inflammatory Actions of Exercise Training.

Authors:  Michael G Flynn; Brian K McFarlin; Melissa M Markofski
Journal:  Am J Lifestyle Med       Date:  2007-05

3.  Circulating IL-18 and the risk of type 2 diabetes in women.

Authors:  M F Hivert; Q Sun; P Shrader; C S Mantzoros; J B Meigs; F B Hu
Journal:  Diabetologia       Date:  2009-08-08       Impact factor: 10.122

4.  Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency.

Authors:  Eric P Zorrilla; Manuel Sanchez-Alavez; Shuei Sugama; Molly Brennan; Rosette Fernandez; Tamas Bartfai; Bruno Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

5.  Behavioral recovery from acute hypoxia is reliant on leptin.

Authors:  Christina L Sherry; Jason M Kramer; Jason M York; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2008-09-27       Impact factor: 7.217

Review 6.  The role of interleukin-18 in the metabolic syndrome.

Authors:  Marius Trøseid; Ingebjørg Seljeflot; Harald Arnesen
Journal:  Cardiovasc Diabetol       Date:  2010-03-23       Impact factor: 9.951

7.  Circulating levels of interleukin-1 family cytokines in overweight adolescents.

Authors:  Christian Jung; Norbert Gerdes; Michael Fritzenwanger; Hans Reiner Figulla
Journal:  Mediators Inflamm       Date:  2010-02-09       Impact factor: 4.711

Review 8.  Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review.

Authors:  John N Fain
Journal:  Mediators Inflamm       Date:  2010-05-23       Impact factor: 4.711

9.  Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome.

Authors:  Minako Yamaoka-Tojo; Taiki Tojo; Kazuki Wakaume; Ryo Kameda; Shinji Nemoto; Naonobu Takahira; Takashi Masuda; Tohru Izumi
Journal:  Nutr Metab (Lond)       Date:  2011-01-20       Impact factor: 4.169

10.  Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men.

Authors:  D Glintborg; L L Christensen; T Kvorning; R Larsen; K Brixen; D M Hougaard; B Richelsen; J M Bruun; M Andersen
Journal:  Mediators Inflamm       Date:  2013-09-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.